Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

ROTIGOTINE LONG-ACTING INJECTION (SYH9087 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

The Board of Directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the dopamine receptor agonist rotigotine long-acting injection (SYH9087 injection) (the "**Product**") developed by the Group has obtained approval from the National Medical Products Administration of the People's Republic of China to conduct clinical trials in China.

The Product is the first long-acting subcutaneous rotigotine product approved for clinical trials in China. Leveraging the Group's long-acting delivery technology platform and based on excipients with excellent biocompatibility, it forms an *in situ* depot following subcutaneous injection, thereby achieving sustained drug delivery. The Product is administered once weekly. Compared with the marketed rotigotine microsphere product, the Product is administered by subcutaneous rather than intramuscular injection, and it does not require reconstitution prior to clinical use. Furthermore, the Product utilises a finer injection needle and a smaller administration volume, which is expected to effectively alleviate patient pain at the injection site, enhancing convenience of clinical application and patient compliance. Preclinical study results demonstrated that, compared with the commercially available microsphere injection, the Product exhibited superior efficacy in the treatment of Parkinson's disease along with a favourable safety profile.

The indication for this clinical trial approval is Parkinson's disease. This clinical trial approval will further enrich the Group's product pipeline in the psychiatric and neurological therapeutic area, and it also represents another important research and development (R&D) achievement for the Group in the field of long-acting formulations. The Group remains committed to developing more drugs with high clinical value and to providing better treatment options for patients.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 9 September 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.